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The prohibitin-repressive interaction with E2F1 is rapidly
inhibited by androgen signalling in prostate cancer cells
S Koushyar1, G Economides1, S Zaat2, W Jiang1, CL Bevan2 and DA Dart1
Prohibitin (PHB) is a tumour suppressor molecule with pleiotropic activities across several cellular compartments including
mitochondria, cell membrane and the nucleus. PHB and the steroid-activated androgen receptor (AR) have an interplay where AR
downregulates PHB, and PHB represses AR. Additionally, their cellular locations and chromatin interactions are in dynamic
opposition. We investigated the mechanisms of cell cycle inhibition by PHB and how this is modulated by AR in prostate cancer.
Using a prostate cancer cell line overexpressing PHB, we analysed the gene expression changes associated with PHB-mediated cell
cycle arrest. Over 1000 gene expression changes were found to be signiﬁcant and gene ontology analysis conﬁrmed PHB-mediated
repression of genes essential for DNA replication and synthesis, for example, MCMs and TK1, via an E2F1 regulated pathway—
agreeing with its G1/S cell cycle arrest activity. PHB is known to inhibit E2F1-mediated transcription, and the PHB:E2F1 interaction
was seen in LNCaP nuclear extracts, which was then reduced by androgen treatment. Upon two-dimensional western blot analysis,
the PHB protein itself showed androgen-mediated charge differentiation (only in AR-positive cells), indicating a potential
dephosphorylation event. Kinexus phosphoprotein array analysis indicated that Src kinase was the main interacting intracellular
signalling hub in androgen-treated LNCaP cells, and that Src inhibition could reduce this AR-mediated charge differentiation. PHB
charge change may be associated with rapid dissociation from chromatin and E2F1, allowing the cell cycle to proceed. The AR and
androgens may deactivate the repressive functions of PHB upon E2F1 leading to cell cycle progression, and indicates a role for AR
in DNA replication licensing.
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INTRODUCTION
Prostate cancer is the most commonly diagnosed male cancer in
the Western world.1 Tumour growth is initially androgen-
dependent; driven by the androgen receptor (AR). Currently, the
mainstays of prostate cancer treatment are androgen ablation
and/or antiandrogen treatment, which block AR signalling.
Hormonal therapies frequently fail and patients may relapse with
‘castrate-resistant’ prostate cancer.2–4 Resistance results from
clonal selection of cells that circumvent androgen requirement
by mechanisms including AR mutation, ampliﬁcation or changes
in AR cofactor (coactivator and corepressor) levels.
One such corepressor is prohibitin (PHB), previously found to be
downregulated by androgen treatment.5 PHB has multiple roles in
the cell, including (i) forming a part of a chaperone in the
inner mitochondrial membrane;6 (ii) an attenuator of Raf-Mek
signalling7,8 and (iii) a repressor of various transcription factors
(including E2Fs and steroid receptors). Additionally, it has tumour
suppressor, antiproliferative and cell cycle regulation activities.
PHB has been shown to repress E2F proteins via recruitment of the
chromatin-condensing proteins HDAC1, N-CoR and BRG1/Brm.9,10
PHB can also repress steroid-activated nuclear receptors, for
example, AR11 and oestrogen receptor (ER),12 and conversely is
capable of activating p53.13 PHB is a potent transcriptional
corepressor of AR and ERα and associates with hormone-regulated
promoters in the absence of hormone, dissociating after
hormone treatment.14 Interestingly, PHB knockdown reduces the
antiproliferative actions of oestrogen antagonists and PHB recruits
BRG1-containing chromatin remodelling complex to antagonist-
bound AR.15,16 Additionally, PHB associates with HP1 proteins,
involved in the compartmentalisation of chromatin into hetero-
chromatin and euchromatin and may facilitate DNA structural
changes required for gene activation and silencing.14
Previously, we showed that PHB-repressed AR activity and
androgen-stimulated growth of LNCaP prostate cancer cells and
that RNA interference-mediated knockdown had the opposite
effects, and sensitised cells to low levels of androgens, both
in vitro and in vivo.5,17 This strongly implicated PHB down-
regulation or inactivation as a mechanism for the sensitisation of
prostate cancer cells to low androgen levels/low potency ligands
during apparent androgen ablation.14
PHB has been reported to inhibit the cell cycle.13,18 Previously,
we generated a stable LNCaP cell line expressing doxycycline-
inducible PHB cDNA, and these cells exhibited cell cycle arrest at
the G1/S boundary, with a signiﬁcant reduction of cells entering
the S phase.17 Additionally, PHB accumulated on the chromatin of
hormonally starved cells. Growth stimulation with hormone or
serum resulted in a rapid reduction of PHB on the chromatin,
followed by a resumed cell cycle entry.
AR inhibits the expression of PHB at the mRNA level via various
mechanisms involving promoter repression and the induction of
AR-induced microRNAs that target PHB.19 The PHB protein in turn
inhibits AR transcriptional activity, resulting in an interesting
feedback loop. However, the androgen-induced downregulation
of PHB mRNA does not account for the rapid androgen-mediated
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dissociation of PHB from the chromatin following androgen
treatment. Such a rapid compartmental movement of a protein
suggests a post-translational modiﬁcation. Androgen actions are
known to be mediated via both genomic and non-genomic
pathways in the cell, and the androgen-mediated regulation of
PHB activity may be via multiple mechanisms.
The repressive association of PHB with E2Fs and RB proteins
suggests a role in the G1 arrest, and the AR has been implicated in
cell cycle initiation20 speciﬁcally at the G1/S boundary, thus
bringing together the function of these proteins. However,
mechanistic details as to how androgen signalling inﬂuences
PHB activity so rapidly remains relatively unknown. To assess this,
we examined the interaction of PHB and E2F1 and whether it
could be modulated by androgen treatment.
RESULTS
PHB overexpression induces cell cycle arrest at G1/S in LNCaP cells
Previously, using a pair of doxycycline-inducible LNCaP cells,
expressing PHB cDNA (or PHB-siRNA) established in Dart et al.,17
we demonstrated that doxycycline-induced PHB ectopic over-
expression signiﬁcantly repressed AR activity in LNCaP cells and
inhibited cell and xenograft growth by cell cycle repression. PHB
loss, conversely, increased androgen-stimulated cell cycle entry,
growth and increased sensitivity to androgens.
Treating LNCaP/PHBcDNA cells with doxycycline induced a
strong ectopic expression of PHB cDNA (and resultant protein
increase), within 16–24 h, which persisted for at least 72 h
(Figures 1a and b). Fluorescence-activated cell sorting (FACS)
analysis revealed a signiﬁcant increase of cells accumulating in G1
within 24–48 h (Figure 1c). PHB overexpression resulted in an
increased number of punctate chromatin-associated foci of PHB in
dox-treated cells (Figure 1d). Wild-type LNCaP cells did not
overexpress PHB or arrest in response to equal doses of
doxycycline.
As PHB is both a nuclear and mitochondrial protein,
we investigated whether PHB overexpression effects could be
due to mitochondrial effects. PHB overexpression was not
associated with overt mitochondrial damage or dysfunction
as 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) and RealTime Glo assays indicated normal function per cell
compared with untreated cells, normalised to cell counts either by
manual counting, Cell Titre Glo or crystal violet assay (see
Supplementary Figure 1). Additionally, no sub-G1 apoptotic
population was detected on FACS analysis or microscopically
visualised using 4',6-diamidino-2-phenylindole-stained dox-
treated cells (Figure 1e). Cells arrested in G1/S by PHB
re-entered the cell cycle when doxycycline was removed from
the media, after 72–96 h (Figure 1f), indicating the absence of
irreversible damage, or indeed permanent quiescence (G0).
PHB overexpression represses genes involved in cell cycle
progression and activates the cyclin-dependent kinase inhibitor
genes
To determine the mechanism of PHB-induced cell cycle arrest,
we used RNA-seq to identify global gene expression changes in
LNCaP prostate cancer cells in response to doxycycline-induced
PHB ectopic cDNA expression. To study the immediate effects of
PHB overexpression, we collected cell samples at 16 h post
treatment with doxycycline—this was sufﬁcient for PHB protein
overexpression but judged to avoid the cell cycle changes being
secondary effects. Doxycycline-induced PHB transcripts were
conﬁrmed in the RNA-seq reads (Figure 2a) (displayed on the
PHB genomic locus, however, most reads emanate from
integrated plasmid located elsewhere) and resulted in signiﬁcant
gene expression changes. Two hundred and ninety-six genes
showed upregulation (P⩽ 0.05, 42-fold) and 916 genes showed
downregulation (P⩽ 0.05, o2-fold) (Figure 2b). Supplementary
Excel sheet lists these genes.
Functional categories and pathways for genes altered by PHB
overexpression
The 1208 signiﬁcant genes were analysed in Metacore (Thomson
Reuters, London, UK), IPA (Ingenuity Pathway Analysis, Qiagen,
Redwood City, CA, USA) Ingenuity and DAVID (Bioinformatics
Resources 6.7; NIH, Bethesda, MD, USA) software. In Metacore, the
‘cell cycle’ regulatory Gene Ontology (GO) pathways represented 4
of the 10 top-scoring pathways, and similarly in the Network
analysis (Figure 2c). IPA and DAVID algorithms also scored ‘cell
cycle’ highest in four out of the ﬁve top GO pathways (Figure 2d).
Other leading networks were involved in Wnt signalling and cell
adhesion. Regulation of the cell cycle via E2F1–4 showed the
highest network relevance in the gene set analysed
(Supplementary Figures 2 and 3). Several E2F-regulated genes,
for example, the MCM family, DNA biosynthetic precursor genes,
for example, TK1 and DHFR, showed strong reduction in the
presence of ectopic PHB cDNA expression. Conversely, the cell
cycle inhibitor genes CDKN1A (p21WAF/CIP1), CDKN1B (p27KIP1) and
GADD45A showed upregulation.
To validate these results, we used a Human Cell Cycle PCR
Low-Density Array (Qiagen), which analysed 88 genes involved in
both positive and negative cell cycle regulation (Supplementary
Figure 4A). This array revealed downregulation of the cell cycle/
DNA replication-promoting genes—MCM2-5, E2F1, cdc25A and TK1
(thymidine kinase 1) after PHB overexpression. The array also
revealed upregulation of the cell cycle inhibitors p21WAF1/CIP1
(CDKN1A), p27KIP1 (CDKN1B), GADD45A and cyclin G2. These gene
expression changes were then further veriﬁed to be signiﬁcant by
quantitative-PCR (q-PCR) of doxycycline-treated LNCaP/PHBcDNA
cells (Figures 2e–h). A subset of these replication regulatory genes
were also analysed in the LNCaP/PHBsiRNA cell line, and showed
opposing regulation (Supplementary Figure 4B). Further, some of
these genes downregulated by PHB also showed upregulation in
androgen-treated LNCaP cells (Supplementary Figure 4C)
PHB represses MCM5 and 6 and TK1 promoter activity
To further investigate the potential mechanism of PHB-mediated
gene repression and cell cycle arrest we generated promoter-
reporter fusions using 600 bp–1.5 kb fragments of the proximal
gene promoters of the PHB-repressed genes TK1 and MCM5, as
well as the upregulated gene CDKN1A, were fused to a luciferase
reporter (pGL4.18; Promega, Madison, WI, USA)—a schematic
diagram is given in Figure 3a. The promoter-reporter fusions
were transiently transfected into either COS-7 cells with
increasing pSG5-PHB expression vector (or empty vector)
or into LNCaP/PHBcDNA cells treated with a range of doxycycline
(0–10 nM), alongside a β-galactosidase control vector. The direct
effect of PHB overexpression on the luciferase promoter-reporter
construct was then analysed. PHB overexpression was conﬁrmed
using western blotting (Figure 3b).
PHB expression repressed TK1, and MCM5 promoter-driven
luciferase activity in a dose-dependent manner, in both COS-7
(Figures 3c and d) and LNCaP/PHBcDNA cells (Figures 3f and g).
MCM5 protein levels were also reduced (see Supplementary
Figure 5C). Additionally, PHB overexpression activated the
promoter of CDKN1A, in a dose-dependent manner in both cell
types (Figures 3e and h).
Analysis using the genome browser (UCSC) and in silico
searches21 revealed potential E2F1 binding sites in these
promoters—the location of which are seen schematically in
Figure 3a. Transfection of LNCaP and COS-7 cells with a construct
overexpressing E2F1 alone resulted in the upregulation of MCM5
and 6 and TK1 and repressed CDKN1A and GADD45A
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(Supplementary Figures 5A and B). Site-directed mutagenesis was
used to change the bases in these potential E2F1 binding sites in
the TK1 gene promoter. In silico searches showed no signiﬁcant
E2F1 potential sites in the resultant mutated sequences. In TK1
promoter mutant A (5′-TCTGCGGC-3′), the base changes abolished
the PHB-mediated repression of this promoter, whereas with TK1
promoter mutant B (5′-TCTCCATC-3′) was still repressed by PHB
(Figures 3i and j). A similar observation was seen when mutating 1
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Figure 1. Doxycycline-induced PHB cDNA expression inhibits cell cycle entry. (a) Q-PCR expression analysis of PHB transcript expression from
LNCaP/PHBcDNA cells treated±doxycycline for 24–72 h, as normalised to β-actin, GAPDH and RPL19 housekeeping genes. (b) Western blot of
PHB and β-actin expression in LNCaP/PHBcDNA cells treated±doxycycline for 24–72 h. Densitometry data for each blot are given underneath.
(c) FACS analysis of LNCaP/PHBcDNA cells treated±doxycycline. Left-hand side represents overlaid histograms of DNA content as measured by
propidium iodide ﬂuorescence. Right-hand side shows a bar chart indicating the cell cycle distribution of LNCaP/PHBcDNA cells
treated±doxycycline. (d) Immunoﬂuorescent staining of PHB expression and localisation in LNCaP/PHBcDNA cells±doxycycline for 24 h
(FITC detection), also DNA (DAPI). Associated bar chart represents number of foci per cell nucleus of LNCaP/PHBcDNA cells
treated±doxycycline for 24 h (from an average cell count of 100). (e) Cell cycle distribution of LNCaP/PHBcDNA cells±doxycycline for 24 h,
and washed and released and allowed to grow for 72 h. Cells show no sub-G1 apoptotic population. (f) Bar graph showing % of
LNCaP/PHBcDNA cells re-entering the S phase 72 h after doxycycline removal from the medium. All data are the mean± s.d. of three
independent experiments performed in triplicate. *Po0.05 and **Po0.01 (t-test analysis).
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Figure 2. PHB overexpression downregulates genes involved in S-phase progression. (a) Histogram of RNA-seq reads of PHB mRNA transcript
fragments from LNCaP/PHBcDNA cells±doxycycline for 16 h overlayed on the gene structure of PHB (RefSeq, 2016)—indicating the
doxycycline-induced overexpression of PHB RNA fragments (from integrated plasmid). (b) Diagram showing the hierarchical clustering
analysis of the 2000+ genes either upregulated or downregulated from LNCaP/PHBcDNA cells±doxycycline (∓2-fold, P⩽ 0.05). Drawn in the
Partek software, blue indicates gene downregulation, and red gene upregulation. (c) Bar charts indicating the most signiﬁcant cellular
processes (left-hand side) and gene networks (right-hand side) inﬂuenced by PHB overexpression. Produced in the Metacore software from a
list of genes (2000)∓ 2-fold, P⩽ 0.05. (d) Table listing the cellular networks associated with the gene expression changes in LNCaP/PHBcDNA
cells±doxycycline, summary from the IPA (Igenuity) and DAVID software. (e–h) Q-PCR validation of genes found to be involved in S-phase
progression (e), in checkpoint activation (f), in DNA replication and AR responsiveness (g) and housekeeping genes (h). All data are the
mean± s.d. of three independent experiments performed in triplicate. *Po0.05 and **Po0.01 (t-test analysis).
Androgens inhibit PHB:E2F1 interaction in prostate cancer
S Koushyar et al
4
Oncogenesis (2017), 1 – 13
Luciferase
Luciferase
Luciferase
Luciferase
-56-118
-140
-90-1080  -1060-1430
pGL4-MCM6
pGl4- TK1
pGL4- CDKN1A
pGL4- MCM5
-40
PHB concentration (ng vector)
R
el
at
iv
e 
lu
ci
fe
ra
se
 e
xp
re
ss
io
n 
(%
)
0 50 10
0
20
0
30
0
40
0
0
50
100
*
PHB concentration (ng vector)
R
el
at
iv
e 
lu
ci
fe
ra
se
 e
xp
re
ss
io
n 
(%
)
0 50 10
0
20
0
30
0
40
0
0
50
100
P H B  c onc e ntra t ion (ng v e c tor)
R
el
at
iv
e 
lu
ci
fe
ra
se
 e
xp
re
ss
io
n 
(%
)
0 50 10
0
20
0
30
0
40
0
0
50
100
150
200
250
TK1-promoter MCM5-promoter CDKN1A-promoter
R
el
at
iv
e 
lu
ci
fe
ra
se
   
ex
pr
es
si
on
 (%
)
pG
L4
-TK
1-W
T
pG
L4
-TK
1-M
UT
A
pG
L4
-TK
1-M
UT
B
0
50
100
150
0
200
400
LuciferasepGl4-TK1
WT 5’-TCTCCCGC-3’
TK1-mutA 5’-TCTGCGGC-3’
TK1-mutB 5’-TCTCCATC-3’
ng PHB
GAPDH
PHB
pS
G
5-
E
m
pt
y
pS
G
5-
P
H
B
TK1-promoter MCM5-promoter
35kDa
28kDa
48kDa
35kDa
**
**
**
*
*
0u
M
2.5
uM 5u
M
0
25
50
75
100
0u
M
2.5
uM 5u
M
0
25
50
75
100
0u
M
2.5
uM 5u
M
10
uM
0
50
100
150
200
CDKN1A-promoter
N
or
m
al
is
ed
 lu
ci
fe
ra
se
 a
ct
iv
ity
10
uM
Do
x
10
uMDo
x Do
x
Figure 3. PHB represses MCM5 and 6, and TK1 promoters, while activating the CDKN1A promoter. (a) Schematic diagram of the promoter-
reporter fusion plasmids generated linked to luciferase. The proximal gene promoter of 500–1000 bp cloned upstream of luciferase.
Numbered lines indicate the position of predicted strong E2F1 binding sites (ALGGEN software). (b) Western blot analysis of PHB expression
levels from COS-7 cells transfected with pSG5-PHB or empty vector (pSG5). (c–e) Luciferase activity in COS-7 cells transfected with TK1
promoter (c), MCM5 promotor (d) and CDKN1A (p21) promoter (e) in the presence of increasing amounts of pSG-PHB vector (0–400 ng) or
empty vector control. Data were normalised to β-galactosidase activity. (f–h) Luciferase activity in LNCaP/PHBcDNA cells treated with increasing
doses of doxycycline and (f) TK1 promoter, (g) MCM5 promoter and (h) CDKN1A promoter. (i) Schematic diagram of the TK1 gene promoter
indicating the E2F1 binding site and the sequences in the TK1 mutant promoters generated. (j) Luciferase activity in COS-7 cells transfected
with TK1 and mutant TK1 promoter reporters with increasing amounts of pSG-PHB vector (0–400 ng) or empty vector. All data are the
mean± s.d. of three independent experiments performed in triplicate. *Po0.05 and **Po0.01 (t-test analysis).
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of the E2F1 binding sites in the MCM6 promoter—see
Supplementary Figure 5D.
PHB and E2F protein:protein interaction is inhibited by androgen
treatment
PHB and E2F1 have been found to interact by various authors,
and here we show they co-immunoprecipitated (co-IP) from
LNCaP nuclear extracts. When IP interactions were analysed
from LNCaP hormonally starved for 72 h or subsequently
treated with R1881 (10 nM) for 4 h (or vehicle), the E2F1:PHB
interaction was reduced by hormone treatment (Figure 4a). Also,
the AR:PHB interaction was also diminished by androgen
treatment. When alkaline phosphatase was introduced into the
IP incubation, the E2F1:PHB interaction was also reduced
(Figure 4b).
To further examine protein interaction, we used two methods:
ﬁrst, we used a mammalian two-hybrid assay system (Checkmate;
Promega), where plasmids expressing PHB fused to yeast
GAL4 DNA-binding domain (pBIND-PHB), and E2F1 fused to the
herpes simplex virus VP16 activation domain (pACT-E2F1) were
Figure 4. PHB:E2F1 interaction is inhibited by androgen treatment. (a) Western blot of PHB levels from PHB, AR and E2F1 immunoprecipitates
from nuclear extracts from LNCaP cells hormonally starved for 72 h followed by treatment with 10 nM R1881 for 4 h. (b) Abrogation of PHB:
E2F1 co-immunoprecipitation when extracts were preincubated with alkaline phosphatase enzyme. (c) Upper panel—schematic diagram of
the Checkmate two-hybrid interaction assay for PHB and E2F1. Lower panel—luciferase activity from LNCaP cell extracts transfected with
components of the checkmate assay including pBINDGal4-PHB and pACT VP16-E2F1, along with empty vector controls. Transfections were
normalised to β-galactosidase. (d) Upper panel—schematic diagram of the NanoBit interaction assay for PHB and E2F1. Lower panel—nano-
luciferase activity in live LNCaP cells grown in charcoal-stripped serum and transfected with components of the NanoBit assay including
pPHB-LargeBit and pE2F1-SmallBit, along with empty vector controls (Halo-tagged Large+SmallBit), positive interaction controls (PRKACA:
PRKAR2A) and positive rapamycin-inducible interaction control (FRB:FKBP). Cells were then treated with androgen and measured again at 2 h.
All data are the mean± s.d. of three independent experiments performed in triplicate. *Po0.05 and **Po0.01 (t-test analysis).
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transfected into cells alongside a Gal4-responsive reporter
plasmid (pGl5-luc) containing ﬁve GAL4 binding sites upstream
of luciferase. Additionally, cells were transfected with negative
control empty vector combinations and positive control plasmids
expressing the MyoD-Id fusion partners. In transiently transfected
LNCaP cells, luciferase activity indicated an interaction between
PHB:E2F1 (Figure 4c). No signal was detected when empty vector
control was used to replace the fusion plasmid.
To overcome the potentially confounding effects of such a
strong repressor (PHB) and a strong activator (E2F1), a second
protein:protein interaction system was used. Here, plasmids
expressing PHB and E2F1 fused to either half of the two-subunit
system based on the NanoLuc luciferase (NanoBit; Promega).
LargeBit-PHB and SmallBit-E2F1 plasmids were transfected
into both hormonally starved COS-7 cells or LNCaP cells,
alongside control vectors including positive interaction
control, a rapamycin-inducible positive interacting control and
Halo-tagged SmallBit vectors and nonspeciﬁc/non-interaction
negative control vectors. This allowed real-time analysis of the
PHB-E2F1 interaction to be monitored in the presence of
Figure 5. AR signalling alters PHB isoelectric charge point. (a) Western blot of PHB associated with the chromatin in LNCaP, VCaP and PC3 cells
grown in media with charcoal-stripped serum for 72 h and then treated with ethanol or R1881 (10 nM) for 4 h. (b) Densitometry data for PHB
(upper panel) and AR (lower) association with the chromatin in PC3, VCaP and LNCaP cells grown in media with charcoal-stripped serum for
72 h and then treated with ethanol or R1881 (10 nM) for 4 h. (c) 2D western blot for PHB from LNCaP cells grown in media with full serum or
charcoal-stripped serum for 72 h. Blot represents isoelectric focussing of pH 3–10 horizontal and protein size vertical (4–12% gradient gel).
(d) 2D western blot of PHB from LNCaP cells grown in media with charcoal-stripped serum for 72 h and then treated with ethanol or 10 nM
R1881, or R1881 together with 10 μM enzalutamide for 4 h. Blot represents isoelectric focussing of pH 3–10 (horizontal) and protein size
(vertical 4–12% gradient gel). Insert ﬁgure shows magniﬁcation and arrow indicates additional basic PHB species. (e) PC3 cells grown in media
with charcoal-stripped serum for 72 h and then treated with ethanol or R1881 (10 nM) for 4 h. Blot represents isoelectric focussing of pH 3–10
(horizontal) and protein size (vertical 4–12% gradient gel). (f) 2D western blot of PHB from LNCaP cells transfected with GFP-tagged PHB, with
isoelectric focussing pH 3–10 and linear 12% acrylamide gel.
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Figure 6. Rapid signalling cascades centred around Src kinase in androgen-treated LNCaP cells leads to PHB charge differentiation.
(a and b) Kinexus protein array data from LNCaP cells grown in media with charcoal-stripped serum for 72 h and then treated with ethanol or
R1881 (10 nM) for 4 h. (a) Phosphorylation changes on components of the cell cycle machinery at G1/S. (b) Phosphorylation events in
intracellular cell signalling proteins. (c) Western blot of total Src and Src (phospho-Tyr418) from LNCaP cells grown in media with charcoal-
stripped serum for 72 h and then treated with ethanol or R1881 (10 nM) for 4 h. Bar graph represents densitometry data. (d) Q-PCR analysis of
androgen-driven PSA expression in LNCaP cells grown in media with charcoal-stripped serum for 72 h and then treated with ethanol or R1881
(10 nM) for 4 h with or without Src inhibitor. (e) 2D western blot of PHB from LNCaP cells grown in media with charcoal-stripped serum for 72 h
and then treated with ethanol or R1881 (10 nM) for 4 h with or without Src inhibitor. Blot represents isoelectric focussing of pH 3–10 horizontal
and protein size vertical (4–12% gradient gel). (f) Luciferase assays of COS-7 cells transfected with pSG5-PHB plasmid and MCM5 and
6 promoter reporters in the presence or absence of Src inhibitor. Transfections normalised to β-galactosidase. (g) Luciferase assay of LNCaP/
PHBcDNA cells grown in full serum, transfected with MCM6 reporter and treated with either doxycycline and enzalutamide for 24 h. Data
represent the average of three independent experiments and is normalised to untreated cells. (h) Western blot of AR, PHB and histone H3
associated with the chromatin of LNCaP cells grown in media with charcoal-stripped serum for 72 h and then treated with ethanol or R1881
(10 nM) for 4 h, with or without Src inhibitor. (i) Bar graph indicating the relative densitometry of chromatin-associated AR, PHB and from
LNCaP cells grown in media with charcoal-stripped serum for 72 h and then treated with ethanol or R1881 (10 nM) for 4 h, with or without Src
inhibitor. All data are the mean± s.d. of three independent experiments performed in triplicate. *Po0.05 and **Po0.01 (t-test analysis).
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androgen, which was added to the LNCaP cells and light emission
measured in real time.
The interaction controls showed a strong light emission
as expected, and the inducible interaction control showed
rapamycin-inducible interaction within 20 min—persisting for over
1 h. Hormonally starved LNCaP cells showed a modest activity
indicating some direct interaction between PHB and E2F1, which
was diminished by treatment with androgen after 1 h (Figure 4d).
Androgen treatment rapidly changes the isoelectric point of PHB
in LNCaP cells, but not in PC3
The androgenic effect upon PHB translocation off chromatin in
LNCaP cells was seen to be very rapid—within 1–2 h14 and
similarly in the AR-expressing cell line VCaP (Figures 5a and b).
However, in the AR-null PC3 cell line, the overall cellular level of
PHB was very low and no changes were seen to the remaining
chromatin-associated PHB with androgen treatment. In LNCaP
cells, the downregulation of PHB by AR via promoter or miRNA
pathways was too slow to account for this change (16–24 h),5
as was the fact that increased PHB was seen in the soluble nuclear
and cytoplasmic compartments, indicating no overall change in
cellular PHB levels17 in this timeframe.
To study this rapid and potentially non-genomic action of
androgens, we hormonally starved LNCaP cells for 72 h in
charcoal-stripped foetal calf serum, and then treated them with
10 nM R1881 for 4 h. These cells were then rapidly lysed either in
9 M urea/thiourea for isoelectric focussing and two-dimensional
(2D) western blotting, or in array lysis buffer for protein kinase
array analysis.
From LNCaP cells grown in full media, 2D western blotting for
PHB showed two large spots (+2 smaller spots) (see Figure 5c,
upper panel). However, from hormonally starved LNCaP cells this
was seen as a single large spot with an isoelectric point of pH5
(approx), with two lesser spots (Figure 5c, lower panel and
Figure 5d, upper panel). After 2–4 h of androgen treatment, the
pattern of PHB changed showing two large spots with a shift
towards the isoelectric point of pH 6 (approx) (see Figure 5d,
lower panel). This indicated that PHB underwent a signiﬁcant
androgen-induced isoelectric change, but with no associated
change in size. This indicates a loss of negative charge that
suggests a dephosphorylation event, or a chemically neutralising
modiﬁcation of a previously charged amino acid, but not a large
ligand/protein conjugation, for example, ubiquitin. This charge
shift could also be inhibited in LNCaP cells treated with R1881
when treated with the antiandrogens enzalutamide (10 μM)—see
Figure 5d. A similar charge shift pattern for PHB could also be
observed in the AR-positive VCaP cells line (see Supplementary
Figure 7C). The AR-deﬁcient PC3 cell line showed two spots for
PHB when grown in full, starved or starved media with added
androgen. A similar pattern was also observed for the HeLa
(AR-null) cell line (Supplementary Figure 7A). The spot pattern was
conﬁrmed to be PHB by repeating the 2D western blot using
cells transfected with GFP-tagged PHB, in which both PHB and
GFP-fused PHB could be seen. 2D western analysis also showed a
shift for E2F1 protein—which underwent a rapid increased in
positive charge in the same timeframe (see Supplementary
Figure 7B).
Src signalling is the major androgen-activated signalling pathway
in LNCaP cells
To analyse potential signalling cascades that are initiated by
androgen treatment, LNCaP cells were hormonally starved for 72 h
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and then treated with 10 nM R1881 for 4 h and rapidly lysed in
strong denaturing buffer. Kinexus array (359 phosphosite-speciﬁc
antibody array) analysis, on the lysates, conﬁrmed that Src
signalling pathway was the most prevalent signalling cascade in
androgen-treated LNCaP cells, with several protein components
having Src as the apical kinase (see Figures 6a and b). Several
members of the cell cycle machinery were also phosphorylated
in response to androgen. These pathways are summarised in
the Supplementary Data and in Supplementary Figures 6A–C.
Src was rapidly phosphorylated on Tyr418 by androgen treatment
(Figure 6c). Tyrosine 418 is located in the catalytic domain of Src
and is one of the autophosphorylation sites. Full catalytic activity
of Src requires phosphorylation of Tyr418.22 The transcriptional
activity of AR was also inhibited by Src inhibitor treatment
(Figure 6d). Androgen treatment in the presence of Src inhibitor
reduced the androgen-mediated PHB charge shift towards pH 6
(Figure 6e), and increased the repressive function of PHB in
transfection assays (Figure 6f). Enzalutamide treatment of
LNCaP/PHBcDNA cells (in full medium) transfected with MCM6
promoter-reporter showed an increased respressive activity of
the luciferase reporter (Figure 6g). Androgen treatment in the
presence of Src inhibitor also reduced androgen-mediated PHB
dissociation from the chromatin (Figures 6h and i).
PHB expression levels are reduced and PHB protein is further
dephosphorylated in bicalutamide-resistant LNCaP cells
We developed a LNCaP cell variant with acquired bicalutamide
resistance by growing cells in increasing bicalutamide concentra-
tions for 6 months. The resultant LNCaP-Bic R cell line showed a
proliferative response to bicalutamide (Figure 7a), whereas the
wild-type LNCaP cell line is strongly inhibited. PHB has been
implicated to be essential for the response to antiandrogens in
prostate cancer and indeed antiestrogens in breast cancer, and
PHB knockdown has been shown to reduce the efﬁcacy of these
agents. Indeed, in these bicalutamide-resistant cells we observed
that PHB transcript levels were reduced by 65% (Figure 7b) and
that the remaining PHB protein was charge-shifted much more
towards pH 10 than in wild-type cells (Figure 7c), under
hormonally starved conditions. No additional AR mutations or
variants were observed in this cell line. When these cells were
treated with the antiandrogen bicalutamide in the presence or
absence of the Src inhibitor, we observed that the wild-type cells
became slightly more sensitive to bicalutamide (Figure 7d).
However, in the presence of the Src inhibitor the LNCaP-Bic R
cells showed no proliferative response to bicalutamide and
showed a partial response to the agent (Figure 7e).
PHB mutagenesis identiﬁes potential modiﬁcation sites
To identify putative PHB phosphorylation sites, the complete
amino-acid sequence was scanned by various software including
Group-based Prediction System, Scansite, Phosphosite and
Netphos2.0. These are summarised in Supplementary Table 1.
This search revealed that human PHB contains 17 serine, 14
threonine and 4 tyrosine consensus sites targeted by various
kinases and phosphatases.
A selection (strongest by analysis score/likelihood) of these
sites in a PHB expression plasmid were mutated to alanine using
site-directed mutagenesis and were used transiently transfect
LNCaP cells, and MCM5 and TK1 endogenous genes analysed.
Although not exhaustive, we did observe a reduction in PHB
repressor potential with amino acids L160A, L163A and L170A
(see Supplementary Figure 8). Additional loss of repression was
seen to a modest degree at K83A, and at K186A, but only for the
MCM5 gene.
DISCUSSION
We set out to analyse how the PHB modulated the cell cycle and
how its activity is regulated by AR in prostate cancer cells. PHB has
been shown to recruit HP1 and HDAC proteins to the DNA on
E2F1/Rb complexes, thus arresting the cell cycle at G1.9,14 Using an
RNA-seq-based approach, we analysed the genes repressed by
PHB overexpression. Our RNA-seq and array data strongly
supported that PHB inhibited the cell cycle via an E2F-related
mechanism, with strong downregulation of the MCM gene family.
MCMs are exclusively required for origin licensing during DNA
replication.23,24 Our evidence suggests that several E2F family
members may be involved—as our studies indicate direct E2F1:
PHB interactions, as well as GO pathways centred around E2F3/4.
The E2F family has a large amount of redundancy and some E2Fs
have context-dependent repressive or activating activities altering
across G04G14G1/S.24 We do not yet know if PHB interacts with
other E2F family members in LNCaP cells.
Other genes involved in DNA replication and nucleotide
biosynthesis, for example, TK1 and DHFR were also strongly
inhibited—genes with known E2F binding sites.25,26 Additionally,
PHB overexpression resulted in the upregulation of the checkpoint
kinase inhibitors CDNK1A and B, which are normally upregulated
by p53. PHB has previously been shown to enhance p53
transcriptional activity.13 PHB has been shown to bind the
RB/E2F in a complex and to bring in repressive proteins for
chromatin condensation. Mutating the E2F1 binding site in the TK
and MCM6 promoters abolished the capability of PHB to repress
this promoter.
E2F1 and PHB co-immunoprecipitated from hormonally starved
LNCaP cell nuclear extracts. However, upon androgen treatment
the resulting co-immunoprecipitation with E2F1 was reduced by
25% or more. This interaction between PHB:E2F1 was reduced in
cell extracts treated with alkaline phosphatase—indicating a
phosphorylation-dependent interaction. In two-hybrid assays,
the interaction between PHB:E2F1 was present and could be
inhibited by androgen treatment, but the interactions were not as
strong as the control two proteins—indicative of PHB:E2F1 being a
part of a larger complex of proteins, for example, Rb, HP1, Brg/Brm
and so on, and not a simple 1:1 relationship.
We examined the effect of androgen signalling on the PHB
protein itself and found that androgen treatment resulted in a
rapid neutralisation of the charge upon a population of PHB
protein, which may relate to dephosphorylation (although further
research is required, as other events are possible). This charge shift
occurred very rapidly, in a similar timescale to PHB dissociation
from chromatin in androgen-treated cells. The androgen-induced
charge shift could also be inhibited by the antiandrogen
enzalutamide. The charge shift and chromatin dissociation was
also seen in AR-positive VCaP cells. Steroids and steroid receptors
have been known to elicit cellular responses in a rapid manner
and are able to interact with and activate intracellular signalling
molecules, for example, MAPK, ERK1/2, and raise Ca2+ levels27–30—
a so-called non-genomic pathway.
Kinexus array analysis for androgen-stimulated phosphorylation
pathways in LNCaP cells showed several key pathways, which may
be involved in this process—several with Src kinase as their main
interacting hub. Although other pathways not covered by the
array are equally valid, Src has been previously implicated in the
non-genomic steroid receptor pathways. The AR has been shown
to interact with the SH3 domain of Src.31,32 Indeed, Src activity was
required for full AR activity as monitored by prostate-speciﬁc
antigen induction. Src inhibition also resulted in reduced
androgen-mediated charge shift of the PHB protein, and
dissociation from the chromatin.
In LNCaP cells with an acquired resistance to bicalutamide—a
historically used antiandrogen in prostate cancer, PHB levels were
reduced and the protein charge shift was seen to be more
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extreme. This would indicate that the dephosphorylation of PHB is
involved or is a consequence of this resistance pathway. Although
Src inhibition did not return the sensitivity of these cells back to
that seen in the wild-type cells, it did increase the sensitivity of
these cells to bicalutamide.
PHB has been shown to be downregulated in advanced
prostate cancer—especially in metastatic deposits—compared
with the normal surrounding cells (GEO GSE691933,34).
Additionally, PHB has been implicated in the correct functioning
of the antiandrogens and indeed the antiestrogens.15 In AR-null
PC3 cells, PHB levels were very low and with the basic PHB species
already present before androgen treatment. This may indicate a
possible deactivation of PHB with disease progression towards
androgen independence. Interestingly, online analysis of prostate
adenocarcinoma DNA sequence (http://www.cbioportal.org,
including TCGA analysis) described no mutations in PHB over a
total of 1382 cases spread over seven clinical data sets. This may
indicate that PHB inactivation by phosphorylation and gene
downregulation may be more important in the mechanism of PHB
involvement in prostate cancer, and may indeed be related to its
essential cellular functions and highly conserved sequence across
species.
Potential PHB phosphorylation site and surface accessibility
analysis revealed several serine, threonine, lysine, leucine
and tyrosine residues potentially targeted by kinases (and
phosphatases). The repressive action of PHB was reduced upon
mutation of the leucine residues to alanine—these included the
nuclear export signal residues L160, L163 and L170. Additionally,
but less so was the K83A (Rb binding pocket) and K186A
(E2F1 binding pocket) residues. Although the mutational analysis
requires much more detail, we can hypothesise that phosphoryla-
tion (or other modiﬁcation) of the nuclear export signal may mask
the export signal, and when removed, PHB may then come off
chromatin and be exported out of the nucleus, thus allowing
androgen-mediated cell cycle entry.
Analysis of the potential phosphorylation sites, listed above,
via KinasePhos2.0 (http://kinasephos2.mbc.nctu.edu.tw) and Phos-
phonet (http://www.phosphonet.ca) implicated GRK (G-protein
coupled receptor kinase) and Akt/PKB (protein kinase B) to be the
most likely kinase that would target PHB for phosphorylation, but
no evidence of the likely phosphatase is available. The AR/PHB
interplay seems to be active on several biological levels. First, and
more rapidly, pathways involving the AR and androgens rapidly
dephosphorylate the PHB protein, which inhibits its repressive
activity either directly or by a change in location off the chromatin.
Second, the AR can downregulate the promoter activity, and third
the AR can ﬁne-tune and decrease PHB mRNA transcripts via an AR-
inducible miR-27a mechanism that targets the 3'-untranslated
region of PHB mRNA.19,35
Interestingly, PC3 cells (AR-null) and HeLa (AR-null) cells showed
both PHB species even in starved serum conditions. The fact that
the AR-null PC3 cells showed no such changes indicate that
PHB dephosphorylation has already occurred via an unknown
mechanism, which in itself may lead cells to become independent
of the AR for their cell cycle initiation. Src constitutive activation in
human tumours frequently occurs and Src (Fyn and Lyn) have
been demonstrated to participate in prostate tumourigenesis.36–39
Overactive protein signalling cascades have been implicated in
several modes of drug resistance including castrate-resistant
prostate cancer.40,41
PHB seems to function as a scaffold, which recruits chromatin-
modifying enzymes to the DNA, for example, HP1 and HDACs,
thus repressing gene activity. PHB may repress E2F proteins, as
well as other transcription factors, for example, AR and ER.
Androgen treatment causes rapid changes in PHB protein charge
and location, causing chromatin dissociation and allowing gene
expression and cell cycle progression. Figure 8 shows our
proposed hypothesis for the mechanism of PHB:AR interaction.
This report also strengthens the evidence that AR may function
as a replication licensing protein in prostate cancer cells as
postulated by D’Antonio et al.42 and reviewed in Balk and
Knudsen,43 especially given the androgen-mediated E2F1 charge
shift (see Supplementary Figure 7B). The development of true
androgen independence in prostate cancer may well be via
oncogenic activation of the intracellular pathways that lead to
replication licensing, bypassing AR.
Figure 8. Androgen signalling inhibits PHB-mediated E2F1 repression, leading to cell cycle progression. Schematic of proposed mechanism for
PHB and AR interaction at G1. Ligand binding to the AR leads to intracellular signalling cascades emanating from Src phosphorylation, leading
to PHB:E2F1 disruption and dissociation of PHB from chromatin. PHB may be potentially dephosphorylated, while E2F1 and Rb are
phosphorylated. E2F1 then goes onto stimulate transcription of genes required for S-phase entry, for example, MCM2-5, DNA polymerases and
nucleotide biosynthesis gene, for example, TK1.
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MATERIALS AND METHODS
Cell culture
Cells were maintained at 37 °C in 5% CO2. LNCaPs were maintained in RPMI
medium with 10% foetal bovine serum (First Link, Wolverhampton, UK)
(ATCC CRL-1740). LNCaP/PHBcDNA and LNCaP/PHBsiRNA cells5 were main-
tained in RPMI medium with 10% doxycycline-free foetal bovine serum
(Clontech, Palo Alto, CA, USA), 12 μg/ml blasticidin (Sigma, Dorset, UK),
0.3 mg/ml zeocin (ThermoFisher, Waltham, MA, USA) and 500 μg/ml G418
(Sigma). COS-7 cells (ECACC 87021302), PC3 cells (ATCC CRL-1435) and
VCaP (ATCC CRL-2876) were maintained in Dulbecco’s modiﬁed Eagle's
medium with 10% foetal bovine serum. Media were supplemented with
2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin
(Sigma). Seventy-two hours before androgen exposure, the medium was
replaced with the ‘starvation medium’ consisting of phenol red-free RPMI
medium (or Dulbecco’s modiﬁed Eagle's medium), supplemented with 5%
charcoal-stripped foetal bovine serum (First Link).
Drug treatments
R1881 ((17b)-17-hydroxy-17-methyl-estra-4,9,11-trien-3-one) was dissolved
in ethanol at a stock solution of 10 mM. Src inhibitor-1 (4-(4′-phenox-
yanilino)-6,7-dimethoxyquinazoline, 6,7-dimethoxy-N-(4-phenoxyphenyl)-
4-quinazolinamine) was obtained from Sigma and was dissolved in
dimethyl sulphoxide.
Cell cycle analysis
Cells were grown 24–72 h±doxycycline, and ﬁxed in 70% ethanol.
Cells were stained with 5 mg/ml propidium iodide and RNaseA treated
(50 mg/ml). Cells were analysed with a FACS Calibur (Beckton-Dickinson,
Oxford, UK), using linear scale forward and side scatter analysis, as well as
DNA content. Single cells were gated and the cell cycle proﬁles measured
from 10000 events per sample.
Transfections
Transient transfections of COS-7 cells were carried out in 24-well plates
using the calcium phosphate precipitation method, using 500 ng of
luciferase reporter, 50 ng of β-galactosidase control vector and 0–400 ng of
PHB expression vector (or pSG5-empty) per well. LNCaP cells were
transiently transfected using Lipofectamine 2000 (ThermoFisher), following
the manufacturer's protocols.
Luciferase assays
Cells were washed in ice-cold phosphate-buffered saline and lysed in
reporter lysis buffer (Promega). Lysate was mixed with 20 μl of 0.2 mg/ml
luciferin substrate (Promega) and light emission was captured using a
Glomax multidetector (Promega). Transfections were normalised to
β-galactosidase activity measured using the β-Gal Assay Kit (Promega).
RNA extraction and reverse transcription–PCR
Total RNA samples were prepared using Trizol (Sigma) and converted to
cDNA using the Reverse Transcription System (Promega). RNA quantity and
quality was assessed by nanodrop spectrophotometer measurements and
using a Bioanalyser 2100 (Agilent Technologies LDA UK Limited,
Stockport, UK).
Quantitative-PCR
Reactions were performed in triplicate on an ABI Prism 7900HT System
(Applied Biosystems, Warrington, UK). Reactions consisted of 2 μl cDNA,
2 μl water, 5 μl 2 × SYBR green PCR Master Mix (Applied Biosystems) and
1 μl speciﬁc primers (0.25 pmol/μl). Primer details are given in the
Supplementary Information. Parameters used were as follows: 50 °C for
2 min, 95 °C for 10 min, 40 cycles of 95 °C for 15 s and 60 °C for 1 min.
Levels were normalised to glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) or L19.
mRNA isolation and RNA-seq analysis
Oligo(dT)25 Dynabeads beads (ThermoFisher) were used to isolate
polyA mRNA from total RNA and veriﬁed using a Bioanalyser 2100
(Agilent Technologies LDA UK Limited). The Ion Total RNA-Seq Kit v2
(ThermoFisher) was used to generate RNA fragment libraries, which were
ligated to adapters for cDNA synthesis. cDNA was then ampliﬁed using Ion
Xpress RNA-seq barcode primers and 3′ primer. The ampliﬁed cDNA was
quantiﬁed with a Qubit analyser (ThermoFisher), and its proﬁle checked for
size distribution and peak concentration on Bioanalyser 2100.
Template preparation and RNA-seq
Libraries were clonally ampliﬁed by emulsion PCR on Ion Sphere Particles
using Ion PI template OT2 200 Kit v3 (ThermoFisher) on an Ion OneTouch
2 system (ThermoFisher). Template-positive Ion Sphere Particles were
enriched using an Ion OneTouch ES (ThermoFisher), and were processed
for sequencing using an Ion Proton 200 Sequencing Kit and were loaded
onto a P1 chip and sequenced with an Ion Proton (ThermoFisher) using
default parameters (single-end, forward sequencing). Base calling, adaptor
trimming, barcode deconvolution and alignment was performed on
Torrent Suite version 3.6 (ThermoFisher) using the STAR RNA-seq aligner
plugin. The number of reads per sample was 15–20 million, with an
average read depth of 500 reads per gene. The mean read length for all
samples was 124 bp with 97% accuracy overall. The Partek Genomic Suite
6.6 software (Partek Incorporated, St Louis, MO, USA) was used to analyse
the data. Reads per kilobase per million normalisation for RNA-seq44 was
used using RefSeq transcript (2016-02-02) annotation followed by a one-
way analysis of variance for gene differential expression. Gene targets
showing a ∓ 2-fold change with P-values of o0.05 were put into DAVID,
Metacore and IPA Ingenuity platforms for pathway and GO analysis.
2D western blot
Cells were lysed in urea/thiourea (9 M) and were then subjected to a
2D clean-up procedure (GE Healthcare Life Sciences, Amersham, UK).
Isoelectric focussing of the samples was carried out using an Immobiline
DryStrip IPG strip (pH 3-10; GE Healthcare) at 8000 V for 8 h. It was then
equilibrated into a reducing solution for 15 min, and then replaced with
5 ml of alkylating solution (100 mM iodoacetamide in NuPAGE LDS sample
buffer (ThermoFisher)). The IPG strip was run through a NuPAGE 4–12%
Bis-Tris Zoom Gel (ThermoFisher) and transferred onto PVDF membranes
for immunoblotting.
Chromatin isolation and in situ cell fractionation
Procedures were carried out as described previously in Dart et al.14
Nuclei were isolated from this protocol for immunoprecipitation
experiments—where they were lysed in IPH buffer (50 mM Tris-HCl,
pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 1 mM PMSF, 50 mM NaF,
2 mM Na2VO3 and protease inhibitor mix (Roche Products Limited, Welwyn
Garden City, UK)) and 600μg of protein extracts were incubated with primary
antibody and then with IgA magnetic beads. Immunoprecipitated proteins
were washed in IPH buffer, and resuspended in sodium dodecyl sulphate
sample buffer for western blotting.
Immunoblotting
Twenty micrograms of cell extract was separated by sodium
dodecyl sulphate–polyacrylamide gel electrophoresis and electroblotted
onto nitrocellulose membranes. Nonspeciﬁc binding was blocked in
tris-buffered saline with 0.05% Tween-20 and 5% (w/v) non-fat-dried milk.
Primary antibodies were PHB mouse monoclonal (MS-261-PO;
ThermoFisher) against GAPDH (SC-32233 (Santa Cruz, CA, USA); 1:5000)
or PHB (SC-28259 (Santa Cruz Biotechnology, Inc., Dallas, TX, USA); 1:1000),
MCM5 (SC-22780; Santa Cruz), E2F1 (SC-193; Santa Cruz). Peroxidase-
labelled rabbit anti-mouse secondary antibodies (Sigma) were used
at 1:2000. The membrane was then incubated in chemiluminescent
substrate (GE Healthcare), and light emission detected by autoradiography.
Kinexus kinase array
Cells were lysed in buffer (20 mM MOPS (pH 7.0), 2 mM EGTA, 5 mM EDTA,
30 mM NaF, 60 mM β-glycerophosphate, 20 mM Na2H2P2O7, 1 mM NaVO4,
1 mM PMSF, 3 mM benzamidine, 5 μM pepstatin A, 10 μM leupeptin,
1% Triton X-100, 1 mM dithiothreitol). Lysates were sent to the Kinexus
Bioinformatics Corporation (Vancouver, BC, Canada) for analysis. The array
consisted of 518 pan-speciﬁc antibodies (for protein expression) and 359
phosphosite-speciﬁc antibodies in duplicate.
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